Literature DB >> 22300641

Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus.

K Singh1, N Kozyr, L Stempora, A D Kirk, C P Larsen, B R Blazar, L S Kean.   

Abstract

Although regulatory T cells (Tregs) suppress allo-immunity, difficulties in their large-scale production and in maintaining their suppressive function after expansion have thus far limited their clinical applicability. Here we have used our nonhuman primate model to demonstrate that significant ex vivo Treg expansion with potent suppressive capacity can be achieved and that Treg suppressive capacity can be further enhanced by their exposure to a short pulse of sirolimus. Both unpulsed and sirolimus-pulsed Tregs (SPTs) are capable of inhibiting proliferation of multiple T cell subpopulations, including CD4(+) and CD8(+) T cells, as well as antigen-experienced CD28(+) CD95(+) memory and CD28(-) CD95(+) effector subpopulations. We further show that Tregs can be combined in vitro with CTLA4-Ig (belatacept) to lead to enhanced inhibition of allo-proliferation. SPTs undergo less proliferation in a mixed lymphocyte reaction (MLR) when compared with unpulsed Tregs, suggesting that Treg-mediated suppression may be inversely related to their proliferative capacity. SPTs also display increased expression of CD25 and CTLA4, implicating signaling through these molecules in their enhanced function. Our results suggest that the creation of SPTs may provide a novel avenue to enhance Treg-based suppression of allo-immunity, in a manner amenable to large-scale ex vivo expansion and combinatorial therapy with novel, costimulation blockade-based immunosuppression strategies. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300641      PMCID: PMC3471086          DOI: 10.1111/j.1600-6143.2011.03963.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  52 in total

1.  Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice.

Authors:  Ying Wang; Geoffrey Camirand; Yan Lin; Monica Froicu; Songyan Deng; Warren D Shlomchik; Fadi G Lakkis; David M Rothstein
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

2.  Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.

Authors:  D J Lo; T A Weaver; L Stempora; A K Mehta; M L Ford; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2010-11-10       Impact factor: 8.086

3.  An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness.

Authors:  Claudio Procaccini; Veronica De Rosa; Mario Galgani; Luisa Abanni; Gaetano Calì; Antonio Porcellini; Fortunata Carbone; Silvia Fontana; Tamas L Horvath; Antonio La Cava; Giuseppe Matarese
Journal:  Immunity       Date:  2010-12-09       Impact factor: 31.745

Review 4.  FOXP3+ regulatory T cells in the human immune system.

Authors:  Shimon Sakaguchi; Makoto Miyara; Cristina M Costantino; David A Hafler
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

5.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Authors:  Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

6.  Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients.

Authors:  Giorgio Raimondi; Tina L Sumpter; Benjamin M Matta; Mahesh Pillai; Natasha Corbitt; Yoram Vodovotz; Zhiliang Wang; Angus W Thomson
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

7.  Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.

Authors:  Katarzyna Bocian; Jan Borysowski; Piotr Wierzbicki; Janusz Wyzgal; Danuta Klosowska; Agata Bialoszewska; Leszek Paczek; Andrzej Górski; Grazyna Korczak-Kowalska
Journal:  Nephrol Dial Transplant       Date:  2009-11-09       Impact factor: 5.992

Review 8.  Plasticity of CD4(+) FoxP3(+) T cells.

Authors:  Xuyu Zhou; Samantha Bailey-Bucktrout; Lukas T Jeker; Jeffrey A Bluestone
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

9.  Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.

Authors:  Tatiana N Golovina; Tatiana Mikheeva; Todd M Brusko; Bruce R Blazar; Jeffrey A Bluestone; James L Riley
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

10.  Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.

Authors:  Tim A Weaver; Ali H Charafeddine; Avinash Agarwal; Alexandra P Turner; Maria Russell; Frank V Leopardi; Robert L Kampen; Linda Stempora; Mingqing Song; Christian P Larsen; Allan D Kirk
Journal:  Nat Med       Date:  2009-07-05       Impact factor: 53.440

View more
  26 in total

1.  Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.

Authors:  Maura Rossetti; Roberto Spreafico; Suzan Saidin; Camillus Chua; Maryam Moshref; Jing Yao Leong; York Kiat Tan; Julian Thumboo; Jorg van Loosdregt; Salvatore Albani
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

2.  Adoptive Cell Therapy with Tregs to Improve Transplant Outcomes: The Promise and the Stumbling Blocks.

Authors:  Mohamed B Ezzelarab; Angus W Thomson
Journal:  Curr Transplant Rep       Date:  2016-10-25

3.  Sequential monitoring and stability of ex vivo-expanded autologous and nonautologous regulatory T cells following infusion in nonhuman primates.

Authors:  H Zhang; H Guo; L Lu; A F Zahorchak; R W Wiseman; G Raimondi; D K C Cooper; M B Ezzelarab; A W Thomson
Journal:  Am J Transplant       Date:  2015-03-17       Impact factor: 8.086

4.  Effects of preexisting autoimmunity on heart graft prolongation after donor-specific transfusion and anti-CD154.

Authors:  Safa Kalache; Parth Lakhani; Peter S Heeger
Journal:  Transplantation       Date:  2014-01-15       Impact factor: 4.939

5.  Restimulation After Cryopreservation and Thawing Preserves the Phenotype and Function of Expanded Baboon Regulatory T Cells.

Authors:  Joshua Weiner; Raimon Duran-Struuck; Jonah Zitsman; Leo Buhler; Hugo Sondermeijer; Alicia N McMurchy; Megan K Levings; Megan Sykes; Adam Griesemer
Journal:  Transplant Direct       Date:  2015-02-01

6.  Induction of Immunosuppressive CD8+CD25+FOXP3+ Regulatory T Cells by Suboptimal Stimulation with Staphylococcal Enterotoxin C1.

Authors:  Juyeun Lee; Nogi Park; Joo Youn Park; Barbara L F Kaplan; Stephen B Pruett; Juw Won Park; Yong Ho Park; Keun Seok Seo
Journal:  J Immunol       Date:  2017-12-13       Impact factor: 5.422

Review 7.  Viewing transplantation immunology through today's lens: new models, new imaging, and new insights.

Authors:  Alex Y Huang; W Nicholas Haining; Deborah S Barkauskas; Jay T Myers; Agne Petrosiute; Aneesah P Garrett; Karnail Singh; Kenneth R Cooke; Leslie S Kean
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-22       Impact factor: 5.742

Review 8.  T Cell Cosignaling Molecules in Transplantation.

Authors:  Mandy L Ford
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis.

Authors:  Hui Yin; Xiangyong Li; Bobin Zhang; Tao Liu; Baohong Yuan; Qian Ni; Shilian Hu; Hongbiao Gu
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

10.  Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.

Authors:  D J Lo; D J Anderson; T A Weaver; F Leopardi; M Song; A B Farris; E A Strobert; J Jenkins; N A Turgeon; A K Mehta; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2013-01-11       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.